Reports: Mylan eyes $4.5B Meda

Pharmaceuticals company Mylan (MYL) is reportedly formulating a largely stock offer to acquire Swedish drug maker Meda (MDABF), which has a market cap of $4.5B, although the U.S. company would probably offer a substantial premium.

A deal could slash Mylan's tax bill if more than 20% of its shares were to be transferred to foreign owners.

The drugs that Mylan would receive include therapies for rheumatoid arthritis, women's health and respiratory disorders.

From other sites
Comments (1)
  • joezapp
    , contributor
    Comments (190) | Send Message
    Two years later, the deal is announced.
    10 Feb, 04:51 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs